Brief: Interpace Diagnostics Reports Qtrly Loss Per Share $0.14

Interpace Biosciences

13/08/2019 13:20

Aug 13 (Reuters) - Interpace Diagnostics Group Inc  IDXG.O :
    * INTERPACE DIAGNOSTICS REPORTS SECOND QUARTER 2019
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * Q2 REVENUE $6.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF
$6.6
MILLION
    * SEES FY 2019 REVENUE $33 MILLION TO $36 MILLION
    * FY2019 REVENUE VIEW $33.0 MILLION -- REFINITIV IBES DATA
    * QTRLY LOSS PER SHARE $0.14
    * INCREASING ITS 2019 ANNUAL NET REVENUE GUIDANCE TO A RANGE
OF
$33 MILLION TO $36 MILLION
    * Q2 EARNINGS PER SHARE VIEW $-0.06, REVENUE VIEW $6.6
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3mrDtz 
Further company coverage:  IDXG.O 

 ((Reuters.Briefs@thomsonreuters.com;))